Trans-replicating RNA

Patent metadata

Field	Value
Publication number	US-12338448-B2
Application number	US-201716086127-A
Country	US
Kind code	B2
Filing date	Mar 13, 2017
Priority date	Mar 21, 2016
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The present invention relates to systems and methods suitable for high-level protein production. In particular, a system comprising two separate RNA molecules is foreseen, each comprising a nucleotide sequence derived from an alphavirus: one RNA molecule comprises a RNA construct for expressing alphavirus replicase, and one RNA molecule comprises a RNA replicon that can be replicated by the replicase in trans. The system of the present invention enables expression of a protein of interest in a cell or organism, but is not associated with undesired virus-particle formation. The present invention is suitable for efficiently and safely producing a protein of interest in a target organism. Respective methods of protein production in vitro and in vivo as well as medical uses are provided herein. The present invention also provides DNA encoding the RNA molecules of the invention, and cells comprising the RNA molecules of the invention.

First claim

The invention claimed is:

1. A system comprising:
(a) an intron-free mRNA construct for expressing alphavirus replicase comprising
(i) a non-viral 5′ UTR,
(ii) an open reading frame encoding the replicase, and
(iii) a non-viral 3′ UTR, and

wherein the mRNA construct for expressing alphavirus replicase does not comprise an internal ribosomal entry site (IRES) element for driving translation of the replicase; and
(b) a RNA replicon that can be replicated by the replicase in trans,
wherein the mRNA construct of (a) for expressing alphavirus replicase comprises a 5′-cap for driving translation of the replicase.

2. The system according to claim 1 , wherein the 5′-cap is a natural 5′-cap or a 5′-cap analog.

3. The system according to claim 1 , wherein the open reading frame encoding the alphavirus replicase comprises the coding region(s) for non-structural proteins required for RNA replication.

4. The system according to claim 1 , wherein the mRNA construct for expressing alphavirus replicase comprises a 3′ poly(A) sequence.

5. The system according to claim 1 , wherein the mRNA construct for expressing alphavirus replicase cannot be replicated by the replicase.

6. The system according to claim 1 , wherein the RNA replicon comprises:
(1) an alphavirus 5′ replication recognition sequence, and
(2) an alphavirus 3′ replication recognition sequence.

7. The system according to claim 6 , wherein the alphavirus 5′ replication recognition sequence and the alphavirus 3′ replication recognition sequence direct replication of the RNA replicon in the presence of the replicase, and/or wherein the alphavirus 5′ replication recognition sequence and the alphavirus 3′ replication recognition sequence are native to the alphavirus from which the replicase is derived.

8. The system according to claim 1 , wherein the RNA replicon comprises a heterologous nucleic acid.

9. The system according to claim 1 , wherein the RNA replicon comprises an open reading frame encoding a protein of interest.

10. The system according to claim 9 , wherein the open reading frame encoding a protein of interest is non-native to the alphavirus from which the replicase is derived, and/or wherein expression of the open reading frame encoding a protein of interest is under the control of a subgenomic promoter.

11. The system according to claim 10 , wherein the subgenomic promoter is native to the alphavirus from which the replicase is derived, and/or wherein the subgenomic promoter is a promoter for a structural protein of an alphavirus.

12. The system according to claim 1 , wherein the RNA replicon comprises a 3′ poly(A) sequence, and/or a 5′-cap.

13. The system according to claim 1 , wherein the mRNA construct for expressing alphavirus replicase and/or the RNA replicon does not comprise an open reading frame encoding an intact alphavirus structural protein.

14. The system according to claim 1 , wherein the alphavirus is Semliki Forest virus or Venezuelan equine encephalitis virus or Sindbis virus or Chikungunya Virus.

15. The system according to claim 1 , wherein the mRNA is (+) strand mRNA.

16. The system according to claim 1 , wherein the mRNA is in vitro transcribed mRNA.

17. The system according to claim 16 , wherein the 5′-cap is a 5′-cap analog.

18. The system according to claim 1 , wherein the mRNA is not fully codon-optimized.

19. The system according to claim 1 , wherein the mRNA is comprised in a pharmaceutical composition comprising nanoparticles.

Assignees

• BioNTech SE
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz

Inventors

• Beissert Tim
• Sahin Ugur
• Perkovic Mario

Classifications

• C12N15/1131

  against viruses · CPC title

• C12N2770/36141

  Use of virus, viral particle or viral elements as a vector · CPC title

• C12N15/79

  Vectors or expression systems specially adapted for eukaryotic hosts · CPC title

• C12N15/64

  General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host · CPC title

• C12N15/00

  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00) · CPC title